|
 |
Faculty |
 |
Statement of Need |
 |
Activity Goal |
 |
Learning Objectives |
 |
Financial Support |
 |
Target Audience |
 |
Credit Information |
Advances in Alzheimer's Disease
neuroscienceCME Multimedia Snack
Premiere Date: Wednesday, November 27, 2013This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, November 27, 2016
Note: Credit Is No Longer Available
 | Charles B. Nemeroff, MD, PhD Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX |
 | Murray A. Raskind, MD, MRM Professor and Vice-Chair, Psychiatry and Behavioral Sciences University of Washington Director, VA Northwest Network (VISN 20) Mental Illness Research Education and Clinical Center (MIRECC) VA Puget Sound Health Care System Seattle, WA |
The National Institutes of Health (NIH) recently funded an exhaustive review by the Agency for Healthcare Research and Quality (AHRQ), performed through its Evidence-Based Practice Centers. This review highlights the presence of critical gaps in current knowledge about Alzheimer’s disease (AD) and the progression of cognitive impairment. In addition to recommending continued research into the science of AD, the review emphasized the need for education to the clinicians who treat individuals with dementia to translate the latest research and emerging therapies into meaningful, clinical approaches. The recently published fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has modified and enhanced the way clinicians will describe dementia and emphasizes the need for earlier assessment of neurocognitive disorders.
This neuroscienceCME Snack™ explores the current and emerging science in the management of individuals with AD and challenges clinicians to keep up-to-date on differential diagnosis (e.g., MCI and AD) and offer the best, evidence-based care for their patients with AD.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is:
Clinicians will use the new diagnostic language in routine clinical practice and will implement routine screening for cognitive impairment for early identification and clinical management of patients with Alzheimer’s disease.
At the end of this CE activity, participants should be able to:
- Articulate the latest diagnostic criteria for Alzheimer’s disease and the need for cognitive screening every six months to improve early identification of cognitive impairment in at-risk patients.
- Analyze the role of biomarkers and positron emission tomography (PET) imaging in the clinical management of Alzheimer’s disease.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Physicians and other health care professionals who manage patients with Alzheimer’s disease.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-13-022-H01-P
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST829 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff has disclosed that he receives grants/research support from the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH). He serves as a consultant to Allergan, Inc.; Eli Lilly and Company; Shire Pharmaceuticals, Inc.; SK Pharma; Roche; Takeda Pharmaceuticals North America, Inc.; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; Skyland Trail; and AstraZeneca Pharmaceuticals (2009). He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Gratitude America; Cook Pharma, Inc. (2010); NovaDel Pharma, Inc; and Skyland Trail. He is a stockholder of CeNeRx BioPharma; NovaDel Pharma, Inc., PharmaNeuroBoost; Reevax Pharmaceuticals LLC; and Xhale, Inc. His other financial Interests include CeNeRx BioPharma and PharmaNeuroBoost. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Raskind has no disclosures to report.
Tony Graham, MD (peer review) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Lilly USA, LLC do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
SN-057-112713-11
